<DOC>
	<DOCNO>NCT01472419</DOCNO>
	<brief_summary>Esophageal squamous cell carcinoma considerably prevalent East Asia . Despite relatively high prevalence esophageal SCC , prognosis poor limit option effective chemotherapy regimen . We attempt identify favorable subgroup patient likely benefit 5- fluorouracil/cisplatin ( FP ) capecitabine/cisplatin ( XP ) chemotherapy first-line treatment.Between January 2000 December 2010 , 239 patient diagnosed recurrent , metastatic esophageal SCC receive either FP XP first-line chemotherapy . Clinicopathologic variables treatment outcome retrospectively collect . analysis treatment outcome palliative chemotherapy metastatic esophageal squamous cell carcinoma make prognostic scoring system . The present study represent large series analyze treatment outcome FP/XP chemotherapy metastatic SCC . Risk-adapted stratification treatment subgroup metastatic SCC patient actively pursue .</brief_summary>
	<brief_title>Prognostic Factor Analysis Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>recurrent , metastatic esophageal SCC receive either FP XP firstline chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>metastatic esophageal squamous cell carcinoma</keyword>
	<keyword>Fluoropyrimidine/platinum-based first-line chemotherapy</keyword>
	<keyword>prognosis</keyword>
</DOC>